Trial · NCT00494481
Adverse events234
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 234
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutropenia | Blood and lymphatic system disorders | Vandetanib Plus Docetaxel | 15 | 33 | |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo Plus Docetaxel | 13 | 29 | |
| other | Leukopenia | Blood and lymphatic system disorders | Vandetanib Plus Docetaxel | 10 | 33 | |
| other | Leukopenia | Blood and lymphatic system disorders | Placebo Plus Docetaxel | 8 | 29 | |
| other | Anaemia | Blood and lymphatic system disorders | Vandetanib Plus Docetaxel | 6 | 33 | |
| other | Anaemia | Blood and lymphatic system disorders | Placebo Plus Docetaxel | 6 | 29 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Vandetanib Plus Docetaxel | 4 | 33 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo Plus Docetaxel | 0 | 29 | |
| other | Febrile Neutropenia | Blood and lymphatic system disorders | Vandetanib Plus Docetaxel | 3 | 33 | |
| other | Febrile Neutropenia | Blood and lymphatic system disorders | Placebo Plus Docetaxel | 0 | 29 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Vandetanib Plus Docetaxel | 3 | 33 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Placebo Plus Docetaxel | 2 | 29 | |
| other | Agranulocytosis | Blood and lymphatic system disorders | Vandetanib Plus Docetaxel | 2 | 33 | |
| other | Agranulocytosis | Blood and lymphatic system disorders | Placebo Plus Docetaxel | 2 | 29 | |
| other | Vertigo | Ear and labyrinth disorders | Vandetanib Plus Docetaxel | 2 | 33 | |
| other | Vertigo | Ear and labyrinth disorders | Placebo Plus Docetaxel | 1 | 29 | |
| other | Lacrimation Increased | Eye disorders | Vandetanib Plus Docetaxel | 2 | 33 | |
| other | Lacrimation Increased | Eye disorders | Placebo Plus Docetaxel | 7 | 29 | |
| other | Conjunctivitis | Eye disorders | Vandetanib Plus Docetaxel | 2 | 33 | |
| other | Conjunctivitis | Eye disorders | Placebo Plus Docetaxel | 3 | 29 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00494481/events